Published in Radiother Oncol on June 05, 2013
Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. Radiother Oncol (2014) 1.06
Radiation oncology in the era of precision medicine. Nat Rev Cancer (2016) 0.97
A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol (2014) 0.96
A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making. Radiother Oncol (2014) 0.95
Concept for individualized patient allocation: ReCompare--remote comparison of particle and photon treatment plans. Radiat Oncol (2014) 0.82
The model-based approach to clinical studies in particle radiotherapy--a new concept in evidence based radiation oncology? Radiother Oncol (2013) 0.82
A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol (2016) 0.80
Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. Radiother Oncol (2016) 0.79
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Breast Cancer Res Treat (2014) 0.76
Oncology scan--demonstrating technology and measuring outcomes in head and neck cancer. Int J Radiat Oncol Biol Phys (2014) 0.75
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol (2017) 0.75
What is the degree of innovation routinely implemented in Dutch radiotherapy centres? A multicentre cross-sectional study. Br J Radiol (2016) 0.75
Predicting Patient-specific Dosimetric Benefits of Proton Therapy for Skull-base Tumors Using a Geometric Knowledge-based Method. Int J Radiat Oncol Biol Phys (2017) 0.75
Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients. PLoS One (2016) 0.75
Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol (2017) 0.75
Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys (2016) 0.75
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Front Oncol (2017) 0.75
Proton therapy in clinical practice: current clinical evidence. J Clin Oncol (2007) 5.31
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Tailoring the atomic structure of graphene nanoribbons by scanning tunnelling microscope lithography. Nat Nanotechnol (2008) 2.49
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol (2010) 2.29
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol (2009) 2.21
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med (2008) 2.08
Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J (2003) 2.06
Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol (2004) 1.94
The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol (2012) 1.87
Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol (2009) 1.76
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (2007) 1.76
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer (2011) 1.76
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol (2012) 1.68
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys (2010) 1.66
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Optimal locoregional treatment in gastric cancer. J Clin Oncol (2005) 1.54
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol (2008) 1.53
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol (2008) 1.51
Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2006) 1.51
Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet (2006) 1.50
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys (2006) 1.48
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol (2010) 1.44
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol (2010) 1.40
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev (2006) 1.35
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs (2003) 1.35
Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2006) 1.34
Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol (2007) 1.34
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys (2004) 1.27
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev (2013) 1.24
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2005) 1.24
Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys (2003) 1.24
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys (2010) 1.23
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.22
A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol (2007) 1.22
The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol (2005) 1.22
A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 1.22
Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des (2008) 1.21
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med (2012) 1.21
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys (2006) 1.20
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer (2012) 1.18
Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem J (2007) 1.18
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys (2005) 1.18
In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol (2004) 1.17
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther (2007) 1.17
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol (2004) 1.17
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys (2009) 1.15
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol (2010) 1.15
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer (2005) 1.14
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys (2004) 1.13
Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiother Oncol (2007) 1.13
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev (2007) 1.12
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol (2012) 1.11
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol (2007) 1.11
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
Anticancer mechanisms and clinical application of alkylphospholipids. Biochim Biophys Acta (2012) 1.11
Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol (2007) 1.10
Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem (2002) 1.10
The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol (2009) 1.09
The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev (2010) 1.08
In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys (2004) 1.08
Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol (2009) 1.08
Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys (2008) 1.08